Biomea Fusion is trading at $0.67, up 14.97% in pre-market, with no identified company-specific announcement explaining the October 23 move. - The latest notable news was October 13 Phase 1 BMF-650 results, which reported weight reduction across dose cohorts; available coverage does not establish this as the cause of the rise. - Major indices were mixed, offering no clear broad-market explanation. - No trading-volume data was available.